Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Department of Clinical Laboratory, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Cancer Res Treat. 2020 Jul;52(3):671-679. doi: 10.4143/crt.2019.387. Epub 2020 Jan 28.
This retrospective study aimed to evaluate the distribution pattern and prognostic value of 21-gene recurrence score (RS) in Chinese patients with mucinous breast cancer (MC) and compared with infiltrating ductal carcinoma (IDC).
Patients diagnosed with MC or IDC from January 2010 to January 2017 were retrospectively recruited. Reverse transcriptase-polymerase chain reaction assay of 21 genes was conducted to calculate the RS. Univariate and multivariate analyses were performed to assess the association between RS and clinicopathological factors. Survival outcomes including disease-free survival (DFS) and overall survival (OS) were estimated by Kaplan-Meier method and compared by log-rank test.
The MC cohort included 128 patients and the IDC cohort included 707 patients. The proportions of patients with a low (RS < 18), intermediate (18-30), or high risk (RS > 30) were 32.0%, 48.4%, and 19.5% in MC cohort, and 26.9%, 46.8% and 26.3% in IDC cohort. The distribution of RS varied significantly according to different Ki-67 index and molecular subtype in both cohorts. Moreover, the receipt of chemotherapy was associated with RS in both cohorts. Among patients with MC, tumor stage was related to the DFS (p=0.040). No significant differences in DFS and OS were found among MC patients in different RS risk groups (OS, p=0.695; DFS, p=0.926).
RS was significantly related to Ki-67 index and molecular subtypes in MC patients, which is similar in IDC patients. However, RS was not able to predict DFS and OS in patients with MC.
本回顾性研究旨在评估 21 基因复发评分（RS）在黏液性乳腺癌（MC）患者中的分布模式和预后价值，并与浸润性导管癌（IDC）进行比较。
回顾性招募 2010 年 1 月至 2017 年 1 月期间诊断为 MC 或 IDC 的患者。采用逆转录-聚合酶链反应检测 21 个基因，计算 RS。采用单因素和多因素分析评估 RS 与临床病理因素的关系。采用 Kaplan-Meier 法估计无病生存（DFS）和总生存（OS）的生存结局，并采用对数秩检验进行比较。
MC 队列包括 128 例患者，IDC 队列包括 707 例患者。MC 队列中低危（RS＜18）、中危（18-30）和高危（RS＞30）患者的比例分别为 32.0%、48.4%和 19.5%，IDC 队列分别为 26.9%、46.8%和 26.3%。在两个队列中，RS 的分布根据不同的 Ki-67 指数和分子亚型存在显著差异。此外，两个队列中，化疗的应用均与 RS 相关。在 MC 患者中，肿瘤分期与 DFS 相关（p=0.040）。在不同 RS 风险组的 MC 患者中，DFS 和 OS 无显著差异（OS，p=0.695；DFS，p=0.926）。
RS 在 MC 患者中与 Ki-67 指数和分子亚型显著相关，与 IDC 患者相似。然而，RS 无法预测 MC 患者的 DFS 和 OS。
